Related Experiment Videos
Evolving therapies: farnesyltransferase inhibitors
W Thomas Purcell1, Ross C Donehower
1The Johns Hopkins Oncology Center, 1650 Orleans Street, Bunting-Blaustein Cancer Research Building, Room 187, Baltimore, MD 21231-2410, USA. rdonehow@jhmi.edu
Abstract:
Farnesyltransferase inhibitors (FTIs) are compounds designed to interfere with the signal transduction of cancer cells containing ras gene mutations. Specifically, FTIs were designed to prevent the farnesylation of Ras and other intracellular proteins, and they have been shown to have an effect on malignant cell proliferation and survival. However, the actual intracellular target of FTIs and the cellular determinants of drug action that correlate with antitumor effects currently are unknown. The following are key questions relating to FTI cell biology and clinical development: 1) Are ras gene mutations required for FTIs to be effective? 2) Does the effect of FTI therapy depend on which ras isoform is active (ie, H-ras, K-ras4A/B, or N-ras) in cancer cells? 3) What level of farnesyltransferase inhibition is required for clinical effect? 4) What surrogate biomarkers can be used to evaluate the biologic effect of FTIs in ongoing clinical trials? 5) What is the mechanism of FTI antitumor activity? Although the preliminary results are encouraging, more understanding of the intracellular mechanism of the FTIs is needed to determine how best to administer them in patients with cancer and to test their antitumor effects.
Insights
Farnesyltransferase inhibitors (FTIs) show promise for treating cancers with ras gene mutations. Further research is needed to understand their precise cellular targets and optimize their clinical use for maximum antitumor effects.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Cell Biology
Background:
- Farnesyltransferase inhibitors (FTIs) target signal transduction in cancer cells with ras gene mutations.
- FTIs prevent protein farnesylation, impacting malignant cell proliferation and survival.
- The precise intracellular targets and determinants of FTI efficacy remain unclear.
Purpose of the Study:
- To investigate key questions in FTI cell biology and clinical development.
- To determine if ras gene mutations are essential for FTI effectiveness.
- To elucidate the mechanism of FTI antitumor activity and identify optimal clinical applications.
Main Methods:
- The study addresses critical questions through a review and analysis of existing research on FTI mechanisms.
- It focuses on understanding the role of ras isoforms (H-ras, K-ras, N-ras) in FTI response.
- It explores the required level of farnesyltransferase inhibition and potential surrogate biomarkers.
Main Results:
- Preliminary results suggest FTIs have an effect on cancer cell proliferation and survival.
- The study highlights the need to identify specific intracellular targets of FTIs.
- Understanding FTI action requires further investigation into ras isoform dependency and inhibition levels.
Conclusions:
- More knowledge on FTI intracellular mechanisms is crucial for effective clinical administration.
- Determining the specific cellular targets will enhance the testing of FTI antitumor effects.
- Further research is needed to optimize FTI therapy for cancer patients.